Previous clinical studies suggested that when compared with conventional therapies used alone, such as NB-UVB, cyclosporine, acitretin capsule, and tacrolimus ointment, the inclusion of TGP could reduce the proinflammatory factor levels of IL-17, IL-23, IL-4, and IFN-γ to improve the progression of psoriasis (Ren and Zhao, 2021; Yi, 2015; Lin et al., 2022; Ding, 2020; Griffiths et al., 2021). The gene discussed is IL4; the disease is psoriasis.